The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 8)
Therapeutic Pipeline Program, 2017
Addex Pharmaceuticals has developed drug discovery tools that can be used to screen its small molecule compound library for positive allosteric modulators (protein regulators) of TrkB, a neuroprotective receptor. We have screened several independent chemical series of a type of chemical compounds, called TrkB PAMs, which can become optimized (improved) to become potential Parkinso...
Researchers: Robert Lutjens, PhD
Research Grant, 2017
Mitochondrial dysfunction (powerhouse of the cell), free-radical induced injury (highly reactive atoms that can be harmful) and inflammatory mechanisms have been proposed to play a key role in the neurodegenerative processes of Parkinson's disease (PD). Mitochon Pharmaceuticals has demonstrated that a once-a-day oral treatment with MP101, a brain-penetrant mitochondrial modulator,...
Researchers: John Gerard Geisler, PhD
Dyskinesia Challenge, 2015
Levodopa is the gold-standard drug for treatment of Parkinson's disease (PD), but chronic use is associated with serious motor complications called levodopa-induced dyskinesia (LID). Once established, LID is very hard to treat and adjustments in medication often result in reduced control of Parkinson's symptoms. The aim of this project is to find biofluid markers...
Researchers: Jan Bert Paul Gramsbergen, PhD
Access to Data and Biospecimens, 2014
A relatively common mutation in the brain derived neurotrophic factor (BDNF) gene exists in the human population. Neurotrophic factors are like brain fertilizers that help neurons grow and stay healthy. This specific mutation — called rs6265 — results in a disruption of release of BDNF. Although the BDNF mutation does not increase the risk of developing Parkinson's disease (PD), it...
Therapeutics Development Initiative, 2010
Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons. No endogenous Nurr1 ligands have been identified, and Nurr1 may be unable to bind compounds directly. Instead we have found Nurr1 may be targeted indirectly through its binding partners. Using receptors tagged with green fluorescent protein (GFP) and Renil...